1
|
Thakur S, Nousome D, Aswath K, Cardenas S, Kumari S, Adewale R, Merino M, Dikoglu E, Veeraraghavan P, Gubbi S, Klubo-Gwiezdzinska J. Abstract 769: Genomic and transcriptomic characterization of benign and malignant struma ovarii. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Struma Ovarii (SO) is a rare ovarian teratoma characterized by the presence of thyroid tissue in >50% of the tumor. The majority of SO are benign; however, malignant transformation occurs in up to 5% of the cases. The molecular foundations of benign and malignant SO are grossly unknown. Therefore, the goal of this study was to perform the first comprehensive genomic and transcriptomic analysis of the benign and malignant SO.
Material and Method: We performed whole-exome sequencing (WES) and targeted RNA-sequencing (seq) on the DNA and RNA extracted from formalin-fixed paraffin-embedded SO tumor tissue samples. WES library was prepared using Agilent’s SureSelect XT HS2 kit, with 4 samples failing the quality assessment (QA). Variants were called from GATK processed WES data and annotated using VEP (with ClinVar and COSMIC databases). The targeted RNA-Seq library was prepared using the TruSight RNA Pan-Cancer Panel kit covering 1385 cancer genes, with all samples passing QA. The clinical characteristics of the study cohort were summarized by percentages for categorical variables and medians with 25-75% interquartile ranges for continuous variables.
Results: The study included 31 tissue samples - 21 benign and 10 malignant, including 6 cases of papillary thyroid cancer (PTC), 3 of follicular variant of PTC, and 1 of follicular thyroid cancer. Patients with benign SO were characterized by the median age at diagnosis of 39 years [33-54], tumor size of 3.1 cm [2.5-5.8], while the patients with malignant SO presented at age of 45 [28-54], tumor size of 6 cm [0.85-14] and metastatic disease in 30% (3/10) - 2 patients with peritoneal metastases and 1 patient with pelvic lymph node metastases. The E1A Binding Protein P300, EP300 (6/27), and Isocitrate dehydrogenase, IDH2 (5/27) were the topmost mutated genes in the SO samples. Malignant SO samples were characterized with the presence of pathogenic variants of KRAS (pQ61L and pG12V), NRAS (pQ61R), TP53 (splice site) mutations, and Nuclear Receptor Binding SET Domain Protein 1 (NSD1) fusion as the most common molecular drivers. Among benign SO samples, the most common driver was Thyroglobulin (TG) fusion with either Guanine Nucleotide binding protein (GNAS) or Rac Family Small GTPase 1 (RAC1). Differential expression analysis showed that the member of tumor suppressor family - tumor protein 63 (TP63) was the most downregulated (Log2FC = -3), while Double-sex and Mab-3 Related Transcription Factor 1 (DMRT1), implicated in the development of germ cell tumors, was the most upregulated gene in malignant SO samples over benign (Log2FC = 2.1; padj<0.05).
Conclusions: In contrast to cancer arising from the thyroid gland, characterized by BRAFV600E as the most common mutation, malignant SO belongs to RAS-like tumors. The downregulation of tumor suppressors and upregulation of DMRT1 might be implicated in the malignant transformation of SO.
Citation Format: Shilpa Thakur, Darryl Nousome, Kshama Aswath, Stephanie Cardenas, Sonam Kumari, Ruth Adewale, Maria Merino, Esra Dikoglu, Padmasree Veeraraghavan, Sriram Gubbi, Joanna Klubo-Gwiezdzinska. Genomic and transcriptomic characterization of benign and malignant struma ovarii [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 769.
Collapse
|
2
|
Vannella KM, Oguz C, Stein SR, Pittaluga S, Dikoglu E, Kanwal A, Ramelli SC, Briese T, Su L, Wu X, Ramos-Benitez MJ, Perez-Valencia LJ, Babyak A, Cha NR, Chung JY, Ylaya K, Madathil RJ, Saharia KK, Scalea TM, Tran QK, Herr DL, Kleiner DE, Hewitt SM, Notarangelo LD, Grazioli A, Chertow DS. Evidence of SARS-CoV-2-Specific T-Cell-Mediated Myocarditis in a MIS-A Case. Front Immunol 2021; 12:779026. [PMID: 34956207 PMCID: PMC8695925 DOI: 10.3389/fimmu.2021.779026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 11/23/2021] [Indexed: 01/14/2023] Open
Abstract
A 26-year-old otherwise healthy man died of fulminant myocarditis. Nasopharyngeal specimens collected premortem tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Histopathological evaluation of the heart showed myocardial necrosis surrounded by cytotoxic T-cells and tissue-repair macrophages. Myocardial T-cell receptor (TCR) sequencing revealed hyper-dominant clones with highly similar sequences to TCRs that are specific for SARS-CoV-2 epitopes. SARS-CoV-2 RNA was detected in the gut, supporting a diagnosis of multisystem inflammatory syndrome in adults (MIS-A). Molecular targets of MIS-associated inflammation are not known. Our data indicate that SARS-CoV-2 antigens selected high-frequency T-cell clones that mediated fatal myocarditis.
Collapse
Affiliation(s)
- Kevin M Vannella
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Cihan Oguz
- National Institute of Allergy and Infectious Diseases Collaborative Bioinformatics Resource, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States.,Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Sydney R Stein
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Stefania Pittaluga
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Esra Dikoglu
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Arjun Kanwal
- Division of Cardiology, Westchester Medical Center, Valhalla, NY, United States
| | - Sabrina C Ramelli
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States
| | - Thomas Briese
- Center for Infection and Immunity, Columbia University Mailman School of Public Health, New York, NY, United States
| | - Ling Su
- Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Xiaolin Wu
- Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Marcos J Ramos-Benitez
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.,Postdoctoral Research Associate Training Program, National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD, United States
| | - Luis J Perez-Valencia
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Ashley Babyak
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Nu Ri Cha
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States
| | - Joon-Yong Chung
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Kris Ylaya
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Ronson J Madathil
- Department of Surgery, Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Kapil K Saharia
- Department of Medicine, Division of Infectious Disease, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Thomas M Scalea
- Department of Surgery, Program in Trauma, R. Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Quincy K Tran
- Department of Emergency Medicine, R. Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Daniel L Herr
- Department of Medicine, Program in Trauma, R. Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, United States
| | - David E Kleiner
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Stephen M Hewitt
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Luigi D Notarangelo
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Alison Grazioli
- Kidney Diseases Branch, Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Daniel S Chertow
- Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.,Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
3
|
Aswath K, Welch J, Gubbi S, Veeraraghavan P, Avadhanula S, Gara SK, Dikoglu E, Merino M, Raffeld M, Xi L, Kebebew E, Klubo-Gwiezdzinska J. Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study. Front Endocrinol (Lausanne) 2021; 12:653401. [PMID: 34326811 PMCID: PMC8315151 DOI: 10.3389/fendo.2021.653401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 06/11/2021] [Indexed: 12/11/2022] Open
Abstract
Familial non-medullary thyroid cancer (FNMTC) is a form of endocrine malignancy exhibiting an autosomal dominant mode of inheritance with largely unknown germline molecular mechanism. Hereditary nonpolyposis colorectal cancer syndrome (HNPCC) is another hereditary autosomal dominant cancer syndrome which, if proven to be caused by germline mutations in mismatch repair genes (MMR)-MLHL, MSH2, MSH6, PMS2, and EPCAM-is called Lynch syndrome (LS). LS results in hereditary predisposition to a number of cancers, especially colorectal and endometrial cancers. Tumors in LS are characterized by microsatellite instability (MSI) and/or loss of MMR protein expression in immunohistochemistry (IHC). MSI is a rare event in thyroid cancer (TC), although it is known to occur in up to 2.5% of sporadic follicular TC cases. There are limited data on the role of germline MMR variants FNMTC. The goal of this study was to analyze the potential clinical and molecular association between HNPCC and FNMTC. We performed a cohort study analyzing the demographic, clinical, and pathologic data of 43 kindreds encompassing 383 participants (104 affected, 279 unaffected), aged 43.5 [7-99] years with FNMTC, and performed high-throughput whole-exome sequencing (WES) of peripheral blood DNA samples of selected 168 participants (54 affected by FNMTC and 114 unaffected). Total affected by thyroid cancer members per family ranged between 2 and 9 patients. FNMTC was more prevalent in women (68.3%) and characterized by a median tumor size of 1.0 [0.2-5.0] cm, multifocal growth in 44%, and gross extrathyroidal extension in 11.3%. Central neck lymph node metastases were found in 40.3% of patients at presentation, 12.9% presented with lateral neck lymph node metastases, and none had distant metastases. Family history screening revealed one Caucasian family meeting the clinical criteria for FNMTC and HNPCC, with five members affected by FNMTC and at least eight individuals reportedly unaffected by HNPCC-associated tumors. In addition, two family members were affected by melanoma. Genome Analysis Tool Kit (GATK) pipeline was used in variant analysis. Among 168 sequenced participants, a heterozygous missense variant in the MSH2 gene (rs373226409; c.2120G>A; p.Cys707Tyr) was detected exclusively in FNMTC- HNPCC- kindred. In this family, the sequencing was performed in one member affected by FNMTC, HPNCC-associated tumors and melanoma, one member affected solely by HNPCC-associated tumor, and one member with FNMTC only, as well as seven unaffected family members. The variant was present in all three affected adults, and in two unaffected children of the affected member, under the age of 18 years, and was absent in non-affected adults. This variant is predicted to be damaging/pathogenic in 17/20 in-silico models. However, immunostaining performed on the thyroid tumor tissue of two affected by FNMTC family members revealed intact nuclear expression of MSH2, and microsatellite stable status in both tumors that were tested. Although the MSH2 p.Cys707Tyr variant is rare with a minor allele frequency (MAF) of 0.00006 in Caucasians; it is more common in the South Asian population at 0.003 MAF. Therefore, the MSH2 variant observed in this family is unlikely to be an etiologic factor of thyroid cancer and a common genetic association between FNMTC and HNPCC has not yet been identified. This is the first report known to us on the co-occurrence of FNMTC and HNPCC. The co-occurrence of FNMTC and HNPCC-associated tumors is a rare event and although presented in a single family in our large FNMTC cohort, a common genetic background between the two comorbidities could not be established.
Collapse
Affiliation(s)
- Kshama Aswath
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - James Welch
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Sriram Gubbi
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Padmasree Veeraraghavan
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Shirisha Avadhanula
- Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, United States
| | - Sudheer Kumar Gara
- National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Esra Dikoglu
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Maria Merino
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Mark Raffeld
- National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Liqiang Xi
- National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
| | - Electron Kebebew
- Department of Surgery, Stanford University, Stanford, CA, United States
| | - Joanna Klubo-Gwiezdzinska
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
4
|
Dikoglu E, Naizhen X, O'Connor LP, Pinto P, Merino MJ. Abstract 360: The dilemma of the current diagnostic tests for MSI in prostate cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Understanding the relationship between tumor genomics and the immune response in cancer has gotten more attention with the advance of immunotherapy. Microsatellite instability (MSI) is a molecular marker that provides prognostic and predictive information in many types of tumors including prostate cancer (PC). In PC, MSI-H and dMMR have been reported anywhere from 1% in primary tumors to up to 12% in metastasis. Reliable testing strategies for MSI/MMR status are critical for clinical management of patients with PC. MSI detection methods include PCR based molecular tests, NGS-based MSI detection or immunohistochemical staining (IHC). We observe technical difficulties in our daily practice with current molecular diagnostic tests.
Design:
We examined MMR protein expression (MSH2, MSH6, MLH1, PMS2) and PD-L1 by IHC in 30 PC.
Results:
Among 30 PC tested, 1 tumor (3%) was completely negative for MLH1 and PMS2 and 1 tumor (3%) revealed loss of PMS2 by IHC even though gene panel did not reveal any mutation in PMS2. The PD-L1 IHC was 44% positive, but the single MMR negative biopsy was PD-L1 negative. PD-L1 expression in PC samples did not show correlation with defective MMR expression.
Conclusion:
In our study, controversial results were obtained. Based on our experience; even though many exons of MMR genes are covered with these panels, there are some exons do not get enough coverage to be analyzed. This low coverage problem creates false negative results. There are also pseudogene pairs of these genes, especially PMS2. For some specific regions, even though there is enough coverage it is impossible to know if the pathogenic variant is on the PMS2 or the pseudogene without additional test. This result suffers from false positive results without a confirmatory test. It is also known that 5% to 11% of MSI-H cases demonstrate intact MMR staining and localization (proficient MMR, pMMR) due to retained antigenicity and nonfunctional protein. So far, in regular practice we use MMR analyzing strategies which set up for colon cancer where the tumor is uniform. PC is more complex; most of the time more than one clone is involving.We believe MSI detection for PC requires improvement the technics of detection, robust set up of testing strategy with high sensitivity and specificity, analyzing strategy and training of pathologists. Due to technical difficulties of the detection, we believe that the prevalence of MSI-high/dMMR PC might be higher than reported in the literature so far.
Citation Format: Esra Dikoglu, Xu Naizhen, Luke P. O'Connor, Peter Pinto, Maria J. Merino. The dilemma of the current diagnostic tests for MSI in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 360.
Collapse
Affiliation(s)
| | - Xu Naizhen
- 2National Institutes of Health, Bethesda, MD
| | | | - Peter Pinto
- 2National Institutes of Health, Bethesda, MD
| | | |
Collapse
|
5
|
O'Connor LP, Lebastchi AH, Fasaye GA, Dikoglu E, Daneshvar MA, Ahdoot M, Merino MJ, Pinto PA. 'Case of the Month' from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with high-risk prostate cancer. BJU Int 2021; 127:171-174. [PMID: 33547722 DOI: 10.1111/bju.15273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Luke P O'Connor
- Center for Cancer Research, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Amir H Lebastchi
- Center for Cancer Research, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Grace-Ann Fasaye
- Center for Cancer Research, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Esra Dikoglu
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Michael A Daneshvar
- Center for Cancer Research, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Michael Ahdoot
- Center for Cancer Research, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Peter A Pinto
- Center for Cancer Research, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
6
|
Ferreira CR, Hackbarth ME, Ziegler SG, Pan KS, Roberts MS, Rosing DR, Whelpley MS, Bryant JC, Macnamara EF, Wang S, Müller K, Hartley IR, Chew EY, Corden TE, Jacobsen CM, Holm IA, Rutsch F, Dikoglu E, Chen MY, Mughal MZ, Levine MA, Gafni RI, Gahl WA. Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet Med 2020; 23:396-407. [PMID: 33005041 PMCID: PMC7867608 DOI: 10.1038/s41436-020-00983-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 09/15/2020] [Accepted: 09/18/2020] [Indexed: 02/07/2023] Open
Abstract
PURPOSE Generalized arterial calcification of infancy (GACI), characterized by vascular calcifications that are often fatal shortly after birth, is usually caused by deficiency of ENPP1. A small fraction of GACI cases result from deficiency of ABCC6, a membrane transporter. The natural history of GACI survivors has not been established in a prospective fashion. METHODS We performed deep phenotyping of 20 GACI survivors. RESULTS Sixteen of 20 subjects presented with arterial calcifications, but only 5 had residual involvement at the time of evaluation. Individuals with ENPP1 deficiency either had hypophosphatemic rickets or were predicted to develop it by 14 years of age; 14/16 had elevated intact FGF23 levels (iFGF23). Blood phosphate levels correlated inversely with iFGF23. For ENPP1-deficient individuals, the lifetime risk of cervical spine fusion was 25%, that of hearing loss was 75%, and the main morbidity in adults was related to enthesis calcification. Four ENPP1-deficient individuals manifested classic skin or retinal findings of PXE. We estimated the minimal incidence of ENPP1 deficiency at ~1 in 200,000 pregnancies. CONCLUSION GACI appears to be more common than previously thought, with an expanding spectrum of overlapping phenotypes. The relationships among decreased ENPP1, increased iFGF23, and rickets could inform future therapies.
Collapse
Affiliation(s)
- Carlos R Ferreira
- Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
| | - Mary E Hackbarth
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Shira G Ziegler
- Departments of Pediatrics and Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Kristen S Pan
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - Mary S Roberts
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - Douglas R Rosing
- Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - Margaret S Whelpley
- Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - Joy C Bryant
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ellen F Macnamara
- Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | | | | | - Iris R Hartley
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - Emily Y Chew
- Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
| | - Timothy E Corden
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Christina M Jacobsen
- Divisions of Endocrinology and Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.,Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | - Ingrid A Holm
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA.,Division of Genetics and Genomics and the Manton Center for Orphan Diseases Research, Boston Children's Hospital, Boston, MA, USA
| | - Frank Rutsch
- Department of General Pediatrics, Muenster University Children's Hospital, Muenster, Germany
| | - Esra Dikoglu
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Marcus Y Chen
- Cardiovascular CT Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - M Zulf Mughal
- Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University Hospital's NHS Trust, Manchester, UK
| | - Michael A Levine
- Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia and the Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Rachel I Gafni
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - William A Gahl
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
7
|
Merino MJ, Dikoglu E, Pinto P, Turkbey B, Dahut W, Chun G, Madan RA, Karzai F. Abstract 618: The morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer: What the pathologist needs to know. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In this study we report the effects of neoadjuvant enzalutamide (enza) plus androgen deprivation therapy (ADT) in the prostatectomy specimens of patients receiving this therapy, and the immunoprofile of the tumors. Prostate cancer is the most common cancer in men, affecting 1 out of 9 men in the US. Treatment for newly diagnosed, non-metastatic, high-risk disease includes surgery or radiation in combination with ADT. Enza, an androgen receptor antagonist, is FDA approved for non-metastatic and metastatic castrate-resistant prostate cancer. Studies have shown intensive androgen receptor targeting for localized disease can lead to complete responses.
Design: Single institution study (NCT02430480) evaluating 6 months of neoadjuvant enza (160 mg daily) plus ADT in patients with high risk non-metastatic prostatic cancer. Twenty-two prostatectomy specimens were evaluated. Specimens were fixed in formalin and paraffin embedded following the protocol established for these specimens. Detailed morphological evaluation was performed and tumors compared with prior diagnostic biopsies. Correlation with prior multiparametric MRI (mpMRI) was done. Sections with tumor were obtained (4mm thickness) and stained for IHC for PTEN antibody (Cell signaling), AR (Abcam) and ERG (Abcam)
Results: Patients ranged in age from 43 to 73 years (med 61years). Prior biopsies included Gleason scores of 7(3+4,5 cases); 7(4+3, 3 cases), 8(4+4, 5 cases),9(4+5, 8 cases), 10(1 case). Grossly, the prostatectomy specimens appeared smaller in size. Reviewing prior mpMRI, it was noted that the median prostate volume decreased by 50.7% after 6 months of treatment. No tumor was identified in 2 cases; one with multiple Gleason grade 8 biopsies and the other one Gleason grade 9 in all prior biopsies. In all except 2 cases, the most striking histologic change was the tumor cells that often resembled fusiform histiocytes growing in discrete clusters or individual cells. Occasional small gland formation was present in some cases. Prominent basal cell hyperplasia was present as well as nodular stromal hyperplasia that in MRI mimic cancer. The amount of tumor present varied from bilateral involvement to 10% of one lobe. Most cases were stage pT2 and pT3. 20 cases were positive for AR, 3 had loss of PTEN and 5 had ERG expression (total 22 cases).
Conclusions: Enzalutamide is a potent antiandrogen with promising results in the neoadjuvant treatment of high-risk prostatic cancer. We report in this study the effect and morphologic changes that occur in the tumor as the result of this therapy. Recognition of these morphologic changes is important since the residual tumor may appear different than the prior diagnostic biopsies.
Citation Format: Maria J. Merino, Esra Dikoglu, Peter Pinto, Baris Turkbey, William Dahut, Guinevere Chun, Ravi A. Madan, Fatima Karzai. The morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer: What the pathologist needs to know [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 618.
Collapse
Affiliation(s)
- Maria J. Merino
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Esra Dikoglu
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Peter Pinto
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Baris Turkbey
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - William Dahut
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Guinevere Chun
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Ravi A. Madan
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Fatima Karzai
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
8
|
Wrzeszczynski KO, Rahman S, Frank MO, Arora K, Shah M, Geiger H, Felice V, Manaa D, Dikoglu E, Khaira D, Chimpiri AR, Michelini VV, Jobanputra V, Darnell RB, Powers S, Choi M. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma. Cold Spring Harb Mol Case Stud 2019; 5:a004424. [PMID: 31519698 PMCID: PMC6913137 DOI: 10.1101/mcs.a004424] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 08/07/2019] [Indexed: 01/08/2023] Open
Abstract
The tumor genome of a patient with advanced pancreatic cancer was sequenced to identify potential therapeutic targetable mutations after standard of care failed to produce any significant overall response. Matched tumor-normal whole-genome sequencing revealed somatic mutations in BRAF, TP53, CDKN2A, and a focal deletion of SMAD4 The BRAF variant was an in-frame deletion mutation (ΔN486_P490), which had been previously demonstrated to be a kinase-activating alteration in the BRAF kinase domain. Working with the Novartis patient assistance program allowed us to treat the patient with the BRAF inhibitor, dabrafenib. The patient's overall clinical condition improved dramatically with dabrafenib. Levels of serum tumor marker dropped immediately after treatment, and a subsequent CT scan revealed a significant decrease in the size of both primary and metastatic lesions. The dabrafenib-induced remission lasted for 6 mo. Preclinical studies published concurrently with the patient's treatment showed that the BRAF in-frame mutation (ΔNVTAP) induces oncogenic activation by a mechanism distinct from that induced by V600E, and that this difference dictates the responsiveness to different BRAF inhibitors. This study describes a dramatic instance of how high-level genomic technology and analysis was necessary and sufficient to identify a clinically logical treatment option that was then utilized and shown to be of clinical value for this individual.
Collapse
Affiliation(s)
| | - Sadia Rahman
- New York Genome Center, New York, New York 10013, USA
| | - Mayu O Frank
- Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York 10065, USA
| | - Kanika Arora
- New York Genome Center, New York, New York 10013, USA
| | - Minita Shah
- New York Genome Center, New York, New York 10013, USA
| | | | | | - Dina Manaa
- New York Genome Center, New York, New York 10013, USA
| | - Esra Dikoglu
- New York Genome Center, New York, New York 10013, USA
| | | | - A Rao Chimpiri
- Renaissance School of Medicine, Department of Radiology, Stony Brook University, Stony Brook, New York 11794, USA
| | | | - Vaidehi Jobanputra
- New York Genome Center, New York, New York 10013, USA
- Columbia University Medical Center, New York, New York 10032, USA
| | - Robert B Darnell
- New York Genome Center, New York, New York 10013, USA
- Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York 10065, USA
- Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10065, USA
| | - Scott Powers
- Renaissance School of Medicine, Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA
| | - Minsig Choi
- Stony Brook Cancer Center, Stony Brook Medicine, Stony Brook, New York 11794, USA
| |
Collapse
|
9
|
Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Med Genomics 2019; 12:114. [PMID: 31375115 PMCID: PMC6676607 DOI: 10.1186/s12920-019-0563-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Mayu O Frank
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA
| | - Takahiko Koyama
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | | | - Nicolas Robine
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Filippo Utro
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Anne-Katrin Emde
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Bo-Juen Chen
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Google, 76 9th Avenue, New York, NY, 10011, USA
| | - Kanika Arora
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Minita Shah
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Heather Geiger
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Vanessa Felice
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Esra Dikoglu
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA
| | - Sadia Rahman
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Xiaolan Fang
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Vladimir Vacic
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: 23&Me, 899 W Evelyn Ave, Mountain View, CA, 94041, USA
| | - Ewa A Bergmann
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, D-79108, Freiburg, Germany
| | - Julia L Moore Vogel
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.,Present address: The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Catherine Reeves
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Depinder Khaira
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Anthony Calabro
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: The Tisch Cancer Institute, 1470 Madison Avenue, New York, NY, 10029, USA
| | - Duyang Kim
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Michelle F Lamendola-Essel
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Cecilia Esteves
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Harvard Medical School, 10 Shattuck Street, Boston, MA, 02115, USA
| | - Phaedra Agius
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Christian Stolte
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - John Boockvar
- Northwell Health, Lenox Hill Hospital, 100 E. 77th Street, New York, NY, 10075, USA
| | - Alexis Demopoulos
- Northwell Health, The Brain Tumor Center, 450 Lakeville Road, Lake Success, Lakeville, NY, 11042, USA
| | | | - John G Golfinos
- New York University, School of Medicine, 550 First Avenue, New York, NY, 10016, USA
| | - Cameron Brennan
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Jeffrey Bruce
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Andrew B Lassman
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Peter Canoll
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Christian Grommes
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Mariza Daras
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Eli Diamond
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Antonio Omuro
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Present address: Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA
| | - Elena Pentsova
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Dana E Orange
- Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.,Hospital for Special Surgery, 535 E. 70th Street, New York, NY, 10021, USA
| | - Stephen J Harvey
- IBM Watson Health, NW Broken Sound Bkwy, Boca Raton, FL, 33487, USA
| | - Jerome B Posner
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | | | - Vaidehi Jobanputra
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Michael C Zody
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - John Kelly
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Laxmi Parida
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | | | - Ajay K Royyuru
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Robert B Darnell
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA. .,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. .,Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.
| |
Collapse
|
10
|
Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Med Genomics 2019; 12:56. [PMID: 31023376 PMCID: PMC6485090 DOI: 10.1186/s12920-019-0500-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 03/28/2019] [Indexed: 12/29/2022] Open
Abstract
Background Prompted by the revolution in high-throughput sequencing and its potential impact for treating cancer patients, we initiated a clinical research study to compare the ability of different sequencing assays and analysis methods to analyze glioblastoma tumors and generate real-time potential treatment options for physicians. Methods A consortium of seven institutions in New York City enrolled 30 patients with glioblastoma and performed tumor whole genome sequencing (WGS) and RNA sequencing (RNA-seq; collectively WGS/RNA-seq); 20 of these patients were also analyzed with independent targeted panel sequencing. We also compared results of expert manual annotations with those from an automated annotation system, Watson Genomic Analysis (WGA), to assess the reliability and time required to identify potentially relevant pharmacologic interventions. Results WGS/RNAseq identified more potentially actionable clinical results than targeted panels in 90% of cases, with an average of 16-fold more unique potentially actionable variants identified per individual; 84 clinically actionable calls were made using WGS/RNA-seq that were not identified by panels. Expert annotation and WGA had good agreement on identifying variants [mean sensitivity = 0.71, SD = 0.18 and positive predictive value (PPV) = 0.80, SD = 0.20] and drug targets when the same variants were called (mean sensitivity = 0.74, SD = 0.34 and PPV = 0.79, SD = 0.23) across patients. Clinicians used the information to modify their treatment plan 10% of the time. Conclusion These results present the first comprehensive comparison of technical and machine augmented analysis of targeted panel and WGS/RNA-seq to identify potential cancer treatments.
Collapse
Affiliation(s)
- Mayu O Frank
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA
| | - Takahiko Koyama
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | | | - Nicolas Robine
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Filippo Utro
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Anne-Katrin Emde
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Bo-Juen Chen
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Google, 76 9th Avenue, New York, NY, 10011, USA
| | - Kanika Arora
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Minita Shah
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Heather Geiger
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Vanessa Felice
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Esra Dikoglu
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA
| | - Sadia Rahman
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Alice Fang
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Vladimir Vacic
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: 23&Me, 899 W Evelyn Ave, Mountain View, CA, 94041, USA
| | - Ewa A Bergmann
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51 D-79108, Freiburg, Germany
| | - Julia L Moore Vogel
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.,Present address: The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Catherine Reeves
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Depinder Khaira
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Anthony Calabro
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: The Tisch Cancer Institute, 1470 Madison Avenue, New York, NY, 10029, USA
| | - Duyang Kim
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Michelle F Lamendola-Essel
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Cecilia Esteves
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Present address: Harvard Medical School, 10 Shattuck Street, Boston, MA, 02115, USA
| | - Phaedra Agius
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - Christian Stolte
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - John Boockvar
- Northwell Health, Lenox Hill Hospital, 100 E. 77th Street, New York, NY, 10075, USA
| | - Alexis Demopoulos
- Northwell Health, The Brain Tumor Center, 450 Lakeville Road, Lake Success, Lakeville, NY, 11042, USA
| | | | - John G Golfinos
- New York University, School of Medicine, 550 First Avenue, New York, NY, 10016, USA
| | - Cameron Brennan
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Jeffrey Bruce
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Andrew B Lassman
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Peter Canoll
- Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Christian Grommes
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Mariza Daras
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Eli Diamond
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Antonio Omuro
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Present address: Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA
| | - Elena Pentsova
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Dana E Orange
- Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.,Hospital for Special Surgery, 535 E. 70th Street, New York, NY, 10021, USA
| | - Stephen J Harvey
- IBM Watson Health, NW Broken Sound Bkwy, Boca Raton, FL, 33487, USA
| | - Jerome B Posner
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | | | - Vaidehi Jobanputra
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA.,Columbia University Medical Center, 710 West 168th Street, New York, NY, 10032, USA
| | - Michael C Zody
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA
| | - John Kelly
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Laxmi Parida
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | | | - Ajay K Royyuru
- IBM Thomas J. Watson Research Center, Yorktown Heights, NY, 10598, USA
| | - Robert B Darnell
- New York Genome Center, 101 Avenue of the Americas, New York, NY, 10013, USA. .,Laboratory of Molecular Neuro-Oncology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. .,Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.
| |
Collapse
|
11
|
Wrzeszczynski KO, Felice V, Abhyankar A, Kozon L, Geiger H, Manaa D, London F, Robinson D, Fang X, Lin D, Lamendola-Essel MF, Khaira D, Dikoglu E, Emde AK, Robine N, Shah M, Arora K, Basturk O, Bhanot U, Kentsis A, Mansukhani MM, Bhagat G, Jobanputra V. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer. J Mol Diagn 2018; 20:822-835. [PMID: 30138725 PMCID: PMC6198246 DOI: 10.1016/j.jmoldx.2018.06.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 05/24/2018] [Accepted: 06/21/2018] [Indexed: 02/07/2023] Open
Abstract
We developed and validated a clinical whole-genome and transcriptome sequencing (WGTS) assay that provides a comprehensive genomic profile of a patient's tumor. The ability to fully capture the mappable genome with sufficient sequencing coverage to precisely call DNA somatic single nucleotide variants, insertions/deletions, copy number variants, structural variants, and RNA gene fusions was analyzed. New York State's Department of Health next-generation DNA sequencing guidelines were expanded for establishing performance validation applicable to whole-genome and transcriptome sequencing. Whole-genome sequencing laboratory protocols were validated for the Illumina HiSeq X Ten platform and RNA sequencing for Illumina HiSeq2500 platform for fresh or frozen and formalin-fixed, paraffin-embedded tumor samples. Various bioinformatics tools were also tested, and CIs for sensitivity and specificity thresholds in calling clinically significant somatic aberrations were determined. The validation was performed on a set of 125 tumor normal pairs. RNA sequencing was performed to call fusions and to confirm the DNA variants or exonic alterations. Here, we present our results and WGTS standards for variant allele frequency, reproducibility, analytical sensitivity, and present limit of detection analysis for single nucleotide variant calling, copy number identification, and structural variants. We show that The New York Genome Center WGTS clinical assay can provide a comprehensive patient variant discovery approach suitable for directed oncologic therapeutic applications.
Collapse
Affiliation(s)
| | | | | | | | | | - Dina Manaa
- New York Genome Center, New York, New York
| | | | | | | | - David Lin
- New York Genome Center, New York, New York
| | | | | | | | | | | | | | | | - Olca Basturk
- Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Umesh Bhanot
- Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Alex Kentsis
- Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pediatrics, Weill Cornell Medical College of Cornell University and Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Govind Bhagat
- Columbia University Medical Center, Columbia University, New York, New York
| | - Vaidehi Jobanputra
- New York Genome Center, New York, New York; Columbia University Medical Center, Columbia University, New York, New York.
| |
Collapse
|
12
|
Basturk O, Berger MF, Yamaguchi H, Adsay V, Askan G, Bhanot UK, Zehir A, Carneiro F, Hong SM, Zamboni G, Dikoglu E, Jobanputra V, Wrzeszczynski KO, Balci S, Allen P, Ikari N, Takeuchi S, Akagawa H, Kanno A, Shimosegawa T, Morikawa T, Motoi F, Unno M, Higuchi R, Yamamoto M, Shimizu K, Furukawa T, Klimstra DS. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol 2017; 30:1760-1772. [PMID: 28776573 DOI: 10.1038/modpathol.2017.60] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 04/18/2017] [Accepted: 04/20/2017] [Indexed: 12/14/2022]
Abstract
Intraductal tubulopapillary neoplasm is a relatively recently described member of the pancreatic intraductal neoplasm family. The more common member of this family, intraductal papillary mucinous neoplasm, often carries genetic alterations typical of pancreatic infiltrating ductal adenocarcinoma (KRAS, TP53, and CDKN2A) but additionally has mutations in GNAS and RNF43 genes. However, the genetic characteristics of intraductal tubulopapillary neoplasm have not been well characterized. Twenty-two intraductal tubulopapillary neoplasms were analyzed by either targeted next-generation sequencing, which enabled the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving all targeted (≥300) genes, or whole-exome sequencing. Three of these intraductal tubulopapillary neoplasms were also subjected to whole-genome sequencing. All intraductal tubulopapillary neoplasms revealed the characteristic histologic (cellular intraductal nodules of back-to-back tubular glands lined by predominantly cuboidal cells with atypical nuclei and no obvious intracellular mucin) and immunohistochemical (immunolabeled with MUC1 and MUC6 but were negative for MUC2 and MUC5AC) features. By genomic analyses, there was loss of CDKN2A in 5/20 (25%) of these cases. However, the majority of the previously reported intraductal papillary mucinous neoplasm-related alterations were absent. Moreover, in contrast to most ductal neoplasms of the pancreas, MAP-kinase pathway was not involved. In fact, 2/22 (9%) of intraductal tubulopapillary neoplasms did not reveal any mutations in the tested genes. However, certain chromatin remodeling genes (MLL1, MLL2, MLL3, BAP1, PBRM1, EED, and ATRX) were found to be mutated in 7/22 (32%) of intraductal tubulopapillary neoplasms and 27% harbored phosphatidylinositol 3-kinase (PI3K) pathway (PIK3CA, PIK3CB, INPP4A, and PTEN) mutations. In addition, 4/18 (18%) of intraductal tubulopapillary neoplasms had FGFR2 fusions (FGFR2-CEP55, FGFR2-SASS6, DISP1-FGFR2, FGFR2-TXLNA, and FGFR2-VCL) and 1/18 (5.5%) had STRN-ALK fusion. Intraductal tubulopapillary neoplasm is a distinct clinicopathologic entity in the pancreas. Although its intraductal nature and some clinicopathologic features resemble those of intraductal papillary mucinous neoplasm, our results suggest that intraductal tubulopapillary neoplasm has distinguishing genetic characteristics. Some of these mutated genes are potentially targetable. Future functional studies will be needed to determine the consequences of these gene alterations.
Collapse
Affiliation(s)
- Olca Basturk
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Michael F Berger
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Volkan Adsay
- Department of Pathology, Emory University, Atlanta, GA, USA
| | - Gokce Askan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Umesh K Bhanot
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Ahmet Zehir
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Fatima Carneiro
- Department of Pathology, Centro Hospitalar São João/Faculty of Medicine of Porto University and Institute for Research and Innovation in Health/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
| | - Seung-Mo Hong
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Giuseppe Zamboni
- Department of Pathology, University of Verona, Ospedale S.C.-Don Calabria-Negrar, Verona, Italy
| | - Esra Dikoglu
- New York Genome Center, Molecular Diagnostics, New York, NY, USA
| | - Vaidehi Jobanputra
- New York Genome Center, Molecular Diagnostics, New York, NY, USA.,Department of Pathology, Colombia University Medical Center, New York, NY, USA
| | | | - Serdar Balci
- Department of Pathology, Emory University, Atlanta, GA, USA
| | - Peter Allen
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Naoki Ikari
- Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan
| | - Shoko Takeuchi
- Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan
| | - Hiroyuki Akagawa
- Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan
| | - Atsushi Kanno
- Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Tooru Shimosegawa
- Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Takanori Morikawa
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Fuyuhiko Motoi
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Michiaki Unno
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Ryota Higuchi
- Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Masakazu Yamamoto
- Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Kyoko Shimizu
- Department of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - Toru Furukawa
- Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan
| | - David S Klimstra
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
13
|
Wrzeszczynski KO, Abhyankar A, Felice V, Dikoglu E, Kozon L, Robine N, Emde AK, Basturk O, Bhanot UK, Kentsis A, Mansukhani M, Bhagat G, Jobanputra V. Abstract 2714: Analytical validation of clinical whole genome and transcriptome sequencing of patient derived tumors: clinical application of whole genome sequencing for reporting targetable variants in cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-2714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Next Generation DNA Sequencing (NGS) technologies are currently being applied in the clinical setting for the treatment of disease. The goal is to use high-throughput sequencing to identify specific variants within each tumor and recommend personalized treatment approaches or clinical trials tailored to the individual’s disease and genomic profile. These assays are comprised of either predefined sequencing panels, where a handpicked set of clinically significant genes are examined within each patient, or are cancer type specific targeted sequencing protocols or whole exome platforms covering only the coding region of the patient’s genome. Whole genome sequencing allows hypothesis-free interrogation of both coding and non-coding regions of the genome revealing more potential therapeutic options than examining a small set of genes or genomic loci. The protocol eliminates sequence capture related bias observed in whole exome or panel sequencing. The New York Genome Center therefore has performed analytical validation of whole genome and transcriptome sequencing (WGTS) of patient derived tumors and matched normals for the purposes of clinical testing and have devised a clinical reporting strategy of significant driver and therapeutic associated mutations. Many clinical NGS guidelines are directed toward targeted panel or exome sequencing validation. Here, we expanded on New York State’s Department of Health NGS guidelines developing them into novel standards applicable to WGTS for the purposes of clinical test validation. We first sequenced a virtual tumor at very high coverage (300x) and downsampled to determine the optimum depth of sequencing necessary for high confidence somatic variant calling across the entire genome. We then validated whole genome sequencing laboratory protocols for DNA and RNA sequencing on a total of 50 specimens derived from fresh frozen (FF) and formalin-fixed paraffin-embedded (FFPE) tumor samples. We performed a series of experiments to assess the accuracy and reliability of the results based on our laboratory and bioinformatics protocols. We performed our validation on the 50 tumor normal pairs, a subset of which had known genomic profiles. Comparisons were also made for variant calling concordance and reproducibility between matched FF and FFPE tumors. Here, we present our validation results and clinical WGTS standards for depth of sequencing, reproducibility, sensitivity, and present limit of detection analysis for SNV calling, copy number identification and structural variants. RNA sequencing is performed to call fusion or exon skipping events and to confirm the DNA variants. The New York Genome Center WGTS clinical assay is intended to provide a more comprehensive patient variant discovery approach suitable for directed oncological therapeutic applications.
Citation Format: Kazimierz O. Wrzeszczynski, Avinash Abhyankar, Vanessa Felice, Esra Dikoglu, Lukasz Kozon, Nicolas Robine, Anne-Katrin Emde, Olca Basturk, Umesh K. Bhanot, Alex Kentsis, Mahesh Mansukhani, Govind Bhagat, Vaidehi Jobanputra. Analytical validation of clinical whole genome and transcriptome sequencing of patient derived tumors: clinical application of whole genome sequencing for reporting targetable variants in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2714. doi:10.1158/1538-7445.AM2017-2714
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Olca Basturk
- 2Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Alex Kentsis
- 2Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | |
Collapse
|
14
|
Lardelli RM, Schaffer AE, Eggens VRC, Zaki MS, Grainger S, Sathe S, Van Nostrand EL, Schlachetzki Z, Rosti B, Akizu N, Scott E, Silhavy JL, Heckman LD, Rosti RO, Dikoglu E, Gregor A, Guemez-Gamboa A, Musaev D, Mande R, Widjaja A, Shaw TL, Markmiller S, Marin-Valencia I, Davies JH, de Meirleir L, Kayserili H, Altunoglu U, Freckmann ML, Warwick L, Chitayat D, Blaser S, Çağlayan AO, Bilguvar K, Per H, Fagerberg C, Christesen HT, Kibaek M, Aldinger KA, Manchester D, Matsumoto N, Muramatsu K, Saitsu H, Shiina M, Ogata K, Foulds N, Dobyns WB, Chi NC, Traver D, Spaccini L, Bova SM, Gabriel SB, Gunel M, Valente EM, Nassogne MC, Bennett EJ, Yeo GW, Baas F, Lykke-Andersen J, Gleeson JG. Biallelic mutations in the 3' exonuclease TOE1 cause pontocerebellar hypoplasia and uncover a role in snRNA processing. Nat Genet 2017; 49:457-464. [PMID: 28092684 PMCID: PMC5325768 DOI: 10.1038/ng.3762] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Accepted: 12/07/2016] [Indexed: 02/08/2023]
Abstract
Deadenylases are best known for degrading the poly(A) tail during mRNA decay. The deadenylase family has expanded throughout evolution and, in mammals, consists of 12 Mg2+-dependent 3'-end RNases with substrate specificity that is mostly unknown. Pontocerebellar hypoplasia type 7 (PCH7) is a unique recessive syndrome characterized by neurodegeneration and ambiguous genitalia. We studied 12 human families with PCH7, uncovering biallelic, loss-of-function mutations in TOE1, which encodes an unconventional deadenylase. toe1-morphant zebrafish displayed midbrain and hindbrain degeneration, modeling PCH-like structural defects in vivo. Surprisingly, we found that TOE1 associated with small nuclear RNAs (snRNAs) incompletely processed spliceosomal. These pre-snRNAs contained 3' genome-encoded tails often followed by post-transcriptionally added adenosines. Human cells with reduced levels of TOE1 accumulated 3'-end-extended pre-snRNAs, and the immunoisolated TOE1 complex was sufficient for 3'-end maturation of snRNAs. Our findings identify the cause of a neurodegenerative syndrome linked to snRNA maturation and uncover a key factor involved in the processing of snRNA 3' ends.
Collapse
Affiliation(s)
- Rea M Lardelli
- University of California San Diego, La Jolla, California, USA
| | - Ashleigh E Schaffer
- University of California San Diego, La Jolla, California, USA.,Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA.,Department of Cellular and Molecular Medicine, Stem Cell Program and Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA
| | - Veerle R C Eggens
- Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands
| | - Maha S Zaki
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt
| | - Stephanie Grainger
- Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA
| | - Shashank Sathe
- Department of Cellular and Molecular Medicine, Stem Cell Program and Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA
| | - Eric L Van Nostrand
- Department of Cellular and Molecular Medicine, Stem Cell Program and Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA
| | - Zinayida Schlachetzki
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Basak Rosti
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Naiara Akizu
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Eric Scott
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Jennifer L Silhavy
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Laura Dean Heckman
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Rasim Ozgur Rosti
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Esra Dikoglu
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Anne Gregor
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Alicia Guemez-Gamboa
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Damir Musaev
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Rohit Mande
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Ari Widjaja
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Tim L Shaw
- University of California San Diego, La Jolla, California, USA
| | - Sebastian Markmiller
- Department of Cellular and Molecular Medicine, Stem Cell Program and Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA
| | - Isaac Marin-Valencia
- Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| | - Justin H Davies
- Department of Paediatric Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Linda de Meirleir
- Pediatric Neurology and Metabolic Diseases, Universitair Ziekenhuis Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Hulya Kayserili
- Medical Genetics Department, Koc University School of Medicine, Istanbul, Turkey
| | - Umut Altunoglu
- Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Istanbul Turkey
| | - Mary Louise Freckmann
- Department of Clinical Genetics, The Canberra Hospital, Woden, Australian Capital Territory, Australia
| | - Linda Warwick
- Australian Capital Territory Genetic Service, The Canberra Hospital, Canberra City, Australian Capital Territory, Australia
| | - David Chitayat
- Department of Pediatrics, Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.,The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Susan Blaser
- Division of Neuroradiology, Department of Diagnostic Imaging, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Ahmet Okay Çağlayan
- Department of Medical Genetics, School of Medicine, Istanbul Bilim University, Istanbul, Turkey.,Yale Program on Neurogenetics, Departments of Neurosurgery, Neurobiology and Genetics, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Kaya Bilguvar
- Department of Genetics, Yale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Huseyin Per
- Division of Pediatric Neurology, Department of Pediatrics, Erciyes University School of Medicine, Kayseri, Turkey
| | - Christina Fagerberg
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - Henrik T Christesen
- Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark
| | - Maria Kibaek
- Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark
| | - Kimberly A Aldinger
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA
| | - David Manchester
- Department of Pediatrics, Clinical Genetics and Metabolism, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA
| | - Naomichi Matsumoto
- Department of Human Genetics, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Kazuhiro Muramatsu
- Department of Pediatrics, Gunma University School of Medicine, Showa-machi, Maebashi City, Japan
| | - Hirotomo Saitsu
- Department of Human Genetics, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.,Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Masaaki Shiina
- Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kazuhiro Ogata
- Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Nicola Foulds
- Southampton University Hospitals Trust, Southampton, UK
| | - William B Dobyns
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA
| | - Neil C Chi
- UCSD Cardiology, University of California San Diego, La Jolla, California, USA
| | - David Traver
- Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA
| | - Luigina Spaccini
- Clinical Genetics Unit, Department of Women, Mother and Neonates, "Vittore Buzzi" Children's Hospital, Istituti Clinici di Perfezionamento, Milan, Italy
| | - Stefania Maria Bova
- Child Neurology Unit, Department of Pediatrics, "Vittore Buzzi" Children Hospital, Istituti Clinici di Perfezionamento, Milan, Italy
| | - Stacey B Gabriel
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
| | - Murat Gunel
- Yale Program on Neurogenetics, Departments of Neurosurgery, Neurobiology and Genetics, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Enza Maria Valente
- Section of Neurosciences, Department of Medicine and Surgery, University of Salerno, Salerno, Italy
| | - Marie-Cecile Nassogne
- Pediatric Neurology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Eric J Bennett
- University of California San Diego, La Jolla, California, USA
| | - Gene W Yeo
- Department of Cellular and Molecular Medicine, Stem Cell Program and Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA.,Department of Physiology, National University of Singapore and Molecular Engineering Laboratory, A*STAR, Singapore
| | - Frank Baas
- Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands
| | | | - Joseph G Gleeson
- University of California San Diego, La Jolla, California, USA.,Laboratory of Pediatric Brain Disease and Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA
| |
Collapse
|
15
|
Jerber J, Zaki MS, Al-Aama JY, Rosti RO, Ben-Omran T, Dikoglu E, Silhavy JL, Caglar C, Musaev D, Albrecht B, Campbell KP, Willer T, Almuriekhi M, Çağlayan AO, Vajsar J, Bilgüvar K, Ogur G, Abou Jamra R, Günel M, Gleeson JG. Biallelic Mutations in TMTC3, Encoding a Transmembrane and TPR-Containing Protein, Lead to Cobblestone Lissencephaly. Am J Hum Genet 2016; 99:1181-1189. [PMID: 27773428 PMCID: PMC5097947 DOI: 10.1016/j.ajhg.2016.09.007] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Accepted: 09/13/2016] [Indexed: 12/13/2022] Open
Abstract
Cobblestone lissencephaly (COB) is a severe brain malformation in which overmigration of neurons and glial cells into the arachnoid space results in the formation of cortical dysplasia. COB occurs in a wide range of genetic disorders known as dystroglycanopathies, which are congenital muscular dystrophies associated with brain and eye anomalies and range from Walker-Warburg syndrome to Fukuyama congenital muscular dystrophy. Each of these conditions has been associated with alpha-dystroglycan defects or with mutations in genes encoding basement membrane components, which are known to interact with alpha-dystroglycan. Our screening of a cohort of 25 families with recessive forms of COB identified six families affected by biallelic mutations in TMTC3 (encoding transmembrane and tetratricopeptide repeat containing 3), a gene without obvious functional connections to alpha-dystroglycan. Most affected individuals showed brainstem and cerebellum hypoplasia, as well as ventriculomegaly. However, the minority of the affected individuals had eye defects or elevated muscle creatine phosphokinase, separating the TMTC3 COB phenotype from typical congenital muscular dystrophies. Our data suggest that loss of TMTC3 causes COB with minimal eye or muscle involvement.
Collapse
Affiliation(s)
- Julie Jerber
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA
| | - Maha S Zaki
- Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo 12311, Egypt
| | - Jumana Y Al-Aama
- Princess Al-Jawhara Al-Brahim Center of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah 21453, Saudi Arabia; Department of Genetic Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21453, Saudi Arabia
| | - Rasim Ozgur Rosti
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA
| | - Tawfeg Ben-Omran
- Clinical and Metabolic Genetics Section, Department of Pediatrics, Hamad Medical Corporation, PO Box 3050, Doha, Qatar; Weill Cornell Medical College, Qatar, Education City, PO Box 24144, Doha, Qatar
| | - Esra Dikoglu
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA
| | - Jennifer L Silhavy
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA
| | - Caner Caglar
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA
| | - Damir Musaev
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA
| | - Beate Albrecht
- Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-Essen, 45122 Essen, Germany
| | - Kevin P Campbell
- Howard Hughes Medical Institute, Departments of Neurology, Internal Medicine, and Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242-1101, USA
| | - Tobias Willer
- Howard Hughes Medical Institute, Departments of Neurology, Internal Medicine, and Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242-1101, USA
| | - Mariam Almuriekhi
- Clinical and Metabolic Genetics Section, Department of Pediatrics, Hamad Medical Corporation, PO Box 3050, Doha, Qatar; Weill Cornell Medical College, Qatar, Education City, PO Box 24144, Doha, Qatar
| | - Ahmet Okay Çağlayan
- Department of Medical Genetics, School of Medicine, Istanbul Bilim University, Istanbul 34394, Turkey
| | - Jiri Vajsar
- Division of Neurology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Kaya Bilgüvar
- Yale Program on Neurogenetics, Departments of Neurosurgery, Neurobiology, and Genetics, School of Medicine, Yale University, New Haven, CT 06510, USA
| | - Gonul Ogur
- Department of Genetics, School of Medicine, Ondokuz Mayis University, 55000 Samsun, Turkey
| | - Rami Abou Jamra
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Philipp-Rosenthal-Str. 55, 04103 Leipzig, Germany; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Murat Günel
- Yale Program on Neurogenetics, Departments of Neurosurgery, Neurobiology, and Genetics, School of Medicine, Yale University, New Haven, CT 06510, USA
| | - Joseph G Gleeson
- Laboratory for Pediatric Brain Disease, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Rady Children's Institute for Genomic Medicine, University of California, San Diego, San Diego, CA 92093, USA.
| |
Collapse
|
16
|
Wrzeszczynski KO, Robine N, Vacic V, Emde AK, Chen BJ, Liao W, Arora K, Shah M, Grabowska EA, Felice V, Dikoglu E, Reeves C, Frank M, Jobanputra V, Zody MC, Bloom T, Darnell RB. Abstract 4497: NYGC glioblastoma clinical outcomes pilot study: Discovering therapeutic potential in glioblastoma through integrative genomics. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Current adjuvant therapeutic options for the treatment of Glioblastoma (GBM) are often determined by limited histological information. Additionally, most GBM clinical trials for targeted chemotherapeutic agents do not distinguish the genetic mutational tumor profiles of the patients recruited and have failed to reach successful treatment endpoints. The New York Genome Center (NYGC) has undertaken a glioblastoma clinical sequencing outcome pilot study to better determine personal treatment options for patients with GBM using integrated genomic data. During the initial phase of this study for 2015 NYGC has performed whole genome sequencing (WGS) on 10 primary GBM tumor-normal pairs, analyzed each patient's tumor for single nucleotide variants, structural variants and copy number alterations. In addition RNA sequencing and a DNA methylation assay were also performed on several of the patients. The patient's genomic profile was then compared to a database of known targeted therapeutic approaches. A final tumor board composed of NYGC scientists, GBM consortium scientists and treating oncologists then reviewed all data prior to identifying a final therapeutic strategy. Data from the first 10 patients revealed RB1 variants to be predominant in half of the patients. SNV's in NF1 or PIK3R1 were also discovered in 4 out of 10 samples. Remaining lower frequency variants occurred in TP53, PDGFRA, PTEN, PIK3CA, ERBB3, SMO, STAG2, ACVR1, NFKB1 and JAK3. Analysis of copy number alterations resulted in 8 of 10 patients containing the characteristic chromosome 7 amplification combined with chromosome 10 deletion, affecting EGFR and PTEN, respectively. Extreme amplification with potential double minute structural variation of EGFR containing the A289V mutation was observed in 2 of 10 samples. Two samples contained a potentially targetable over-amplification of the PDGFRA/KIT/KDR chromosome 4 locus. Predominant deletions resided in CDKN2A, ESR2, PTEN and FLT3. Hemizygous deletions of RB1 combined with RB1 nonsense or missense variants were observed in 4 samples. To date, RNA sequencing was performed on 5 patient samples. Most strikingly the combination of DNA and RNA sequencing revealed the presence of a putative activating MET exon skipping event in the extracellular domain. This MET variant was considered as a potential targetable variant. Therapeutic options resulting from WGS genomic profiles were the PI3K inhibitor BKM120 (60%), half of these had an additional aberration in MET and were recommended for the combinatorial trial NCT01870726. Drug recommendations for the treatment of GBM based on specific N = 1 patient genomic profiles were also made for nilotinib, vismodegib and palbociclib. Here, we present the first phase of the NYGC GBM clinical outcome study demonstrating how patient WGS information can provide more precise therapeutic options in the treatment of glioblastoma.
Citation Format: Kazimierz O. Wrzeszczynski, Nicolas Robine, Vladimir Vacic, Anne-Katrin Emde, Bo-Juen Chen, Will Liao, Kanika Arora, Minita Shah, Ewa A. Grabowska, Vanessa Felice, Esra Dikoglu, Catherine Reeves, Mayu Frank, Vaidehi Jobanputra, Michael C. Zody, Toby Bloom, Robert B. Darnell. NYGC glioblastoma clinical outcomes pilot study: Discovering therapeutic potential in glioblastoma through integrative genomics. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4497.
Collapse
Affiliation(s)
| | | | | | | | | | - Will Liao
- New York Genome Center, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kiper POS, Saito H, Gori F, Unger S, Hesse E, Yamana K, Kiviranta R, Solban N, Liu J, Brommage R, Boduroglu K, Bonafé L, Campos-Xavier B, Dikoglu E, Eastell R, Gossiel F, Harshman K, Nishimura G, Girisha KM, Stevenson BJ, Takita H, Rivolta C, Superti-Furga A, Baron R. Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. N Engl J Med 2016; 374:2553-2562. [PMID: 27355534 PMCID: PMC5070790 DOI: 10.1056/nejmoa1509342] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Cortical-bone fragility is a common feature in osteoporosis that is linked to nonvertebral fractures. Regulation of cortical-bone homeostasis has proved elusive. The study of genetic disorders of the skeleton can yield insights that fuel experimental therapeutic approaches to the treatment of rare disorders and common skeletal ailments. METHODS We evaluated four patients with Pyle's disease, a genetic disorder that is characterized by cortical-bone thinning, limb deformity, and fractures; two patients were examined by means of exome sequencing, and two were examined by means of Sanger sequencing. After a candidate gene was identified, we generated a knockout mouse model that manifested the phenotype and studied the mechanisms responsible for altered bone architecture. RESULTS In all affected patients, we found biallelic truncating mutations in SFRP4, the gene encoding secreted frizzled-related protein 4, a soluble Wnt inhibitor. Mice deficient in Sfrp4, like persons with Pyle's disease, have increased amounts of trabecular bone and unusually thin cortical bone, as a result of differential regulation of Wnt and bone morphogenetic protein (BMP) signaling in these two bone compartments. Treatment of Sfrp4-deficient mice with a soluble Bmp2 receptor (RAP-661) or with antibodies to sclerostin corrected the cortical-bone defect. CONCLUSIONS Our study showed that Pyle's disease was caused by a deficiency of sFRP4, that cortical-bone and trabecular-bone homeostasis were governed by different mechanisms, and that sFRP4-mediated cross-regulation between Wnt and BMP signaling was critical for achieving proper cortical-bone thickness and stability. (Funded by the Swiss National Foundation and the National Institutes of Health.).
Collapse
|
18
|
Zaki MS, Bhat G, Sultan T, Issa M, Jung HJ, Dikoglu E, Selim L, G Mahmoud I, Abdel-Hamid MS, Abdel-Salam G, Marin-Valencia I, Gleeson JG. PYCR2 Mutations cause a lethal syndrome of microcephaly and failure to thrive. Ann Neurol 2016; 80:59-70. [PMID: 27130255 DOI: 10.1002/ana.24678] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 03/18/2016] [Accepted: 04/17/2016] [Indexed: 01/09/2023]
Abstract
OBJECTIVE A study was undertaken to characterize the clinical features of the newly described hypomyelinating leukodystrophy type 10 with microcephaly. This is an autosomal recessive disorder mapped to chromosome 1q42.12 due to mutations in the PYCR2 gene, encoding an enzyme involved in proline synthesis in mitochondria. METHODS From several international clinics, 11 consanguineous families were identified with PYCR2 mutations by whole exome or targeted sequencing, with detailed clinical and radiological phenotyping. Selective mutations from patients were tested for effect on protein function. RESULTS The characteristic clinical presentation of patients with PYCR2 mutations included failure to thrive, microcephaly, craniofacial dysmorphism, progressive psychomotor disability, hyperkinetic movements, and axial hypotonia with variable appendicular spasticity. Patients did not survive beyond the first decade of life. Brain magnetic resonance imaging showed global brain atrophy and white matter T2 hyperintensities. Routine serum metabolic profiles were unremarkable. Both nonsense and missense mutations were identified, which impaired protein multimerization. INTERPRETATION PYCR2-related syndrome represents a clinically recognizable condition in which PYCR2 mutations lead to protein dysfunction, not detectable on routine biochemical assessments. Mutations predict a poor outcome, probably as a result of impaired mitochondrial function. Ann Neurol 2016;80:59-70.
Collapse
Affiliation(s)
- Maha S Zaki
- Human Genetics and Genome Research Division, Clinical Genetics Department, National Research Center, Cairo, Egypt
| | - Gifty Bhat
- Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, Rockefeller University, New York, NY
- Division of Pediatric Genetics, Children's Hospital at Montefiore, Bronx, NY
| | - Tipu Sultan
- Pediatric Neurology, Institute of Child Health, Children Hospital, Lahore, Pakistan
| | - Mahmoud Issa
- Human Genetics and Genome Research Division, Clinical Genetics Department, National Research Center, Cairo, Egypt
| | - Hea-Jin Jung
- Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, Rockefeller University, New York, NY
| | - Esra Dikoglu
- Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, Rockefeller University, New York, NY
| | - Laila Selim
- Cairo University Children's Hospital, Division of Neurology and Metabolic Disease, Cairo, Egypt
| | - Imam G Mahmoud
- Cairo University Children's Hospital, Division of Neurology and Metabolic Disease, Cairo, Egypt
| | - Mohamed S Abdel-Hamid
- Department of Medical Molecular Genetics, Human Genetics and Genome Research Division, National Research Center, Cairo, Egypt
| | - Ghada Abdel-Salam
- Human Genetics and Genome Research Division, Clinical Genetics Department, National Research Center, Cairo, Egypt
| | - Isaac Marin-Valencia
- Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, Rockefeller University, New York, NY
| | - Joseph G Gleeson
- Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, Rockefeller University, New York, NY
| |
Collapse
|
19
|
Rosti RO, Dikoglu E, Zaki MS, Abdel-Salam G, Makhseed N, Sese JC, Musaev D, Rosti B, Harbert MJ, Jones MC, Vaux KK, Gleeson JG. Extending the mutation spectrum for Galloway-Mowat syndrome to include homozygous missense mutations in the WDR73 gene. Am J Med Genet A 2016; 170A:992-8. [PMID: 27001912 DOI: 10.1002/ajmg.a.37533] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Accepted: 12/11/2015] [Indexed: 11/10/2022]
Abstract
Galloway-Mowat syndrome is a rare autosomal-recessive disorder classically described as the combination of microcephaly and nephrotic syndrome. Recently, homozygous truncating mutations in WDR73 (WD repeat domain 73) were described in two of 31 unrelated families with Galloway-Mowat syndrome which was followed by a report of two sibs in an Egyptian consanguineous family. In this report, seven affecteds from four families showing biallelic missense mutations in WDR73 were identified by exome sequencing and confirmed to follow a recessive model of inheritance. Three-dimensional modeling predicted conformational alterations as a result of the mutation, supporting pathogenicity. An additional 13 families with microcephaly and renal phenotype were negative for WDR73 mutations. Missense mutations in the WDR73 gene are reported for the first time in Galloway-Mowat syndrome. A detailed phenotypic comparison of all reported WDR73-linked Galloway-Mowat syndrome patients with WDR73 negative patients showed that WDR73 mutations are limited to those with classical Galloway-Mowat syndrome features, in addition to cerebellar atrophy, thin corpus callosum, brain stem hypoplasia, occasional coarse face, late-onset and mostly slow progressive nephrotic syndrome, and frequent epilepsy.
Collapse
Affiliation(s)
- Rasim O Rosti
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| | - Esra Dikoglu
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| | - Maha S Zaki
- Division of Human Genetics and Genome Research, Department of Clinical Genetics, National Research Centre, Cairo, Egypt
| | - Ghada Abdel-Salam
- Division of Human Genetics and Genome Research, Department of Clinical Genetics, National Research Centre, Cairo, Egypt
| | - Nawal Makhseed
- Pediatric Department, Al-Jahra Hospital, Jahra City, Kuwait
| | - Jordan C Sese
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| | - Damir Musaev
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| | - Basak Rosti
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| | - Mary J Harbert
- Rady Children's Hospital, Department of Pediatrics, Sharp Mary Birch Hospital, University of California San Diego School of Medicine, San Diego, California
| | - Marilyn C Jones
- Rady Children's Hospital, Department of Pediatrics, Sharp Mary Birch Hospital, University of California San Diego School of Medicine, San Diego, California
| | - Keith K Vaux
- Division of Medical Genetics, Department of Medicine, University of California San Diego School of Medicine, San Diego, California
| | - Joseph G Gleeson
- Laboratory for Pediatric Brain Diseases, Howard Hughes Medical Institute, The Rockefeller University, New York City, New York
| |
Collapse
|
20
|
Royer-Bertrand B, Castillo-Taucher S, Moreno-Salinas R, Cho TJ, Chae JH, Choi M, Kim OH, Dikoglu E, Campos-Xavier B, Girardi E, Superti-Furga G, Bonafé L, Rivolta C, Unger S, Superti-Furga A. Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia. Sci Rep 2015; 5:17154. [PMID: 26598328 PMCID: PMC4657157 DOI: 10.1038/srep17154] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Accepted: 10/26/2015] [Indexed: 11/18/2022] Open
Abstract
We and others have reported mutations in LONP1, a gene coding for a mitochondrial chaperone and protease, as the cause of the human CODAS (cerebral, ocular, dental, auricular and skeletal) syndrome (MIM 600373). Here, we delineate a similar but distinct condition that shares the epiphyseal, vertebral and ocular changes of CODAS but also included severe microtia, nasal hypoplasia, and other malformations, and for which we propose the name of EVEN-PLUS syndrome for epiphyseal, vertebral, ear, nose, plus associated findings. In three individuals from two families, no mutation in LONP1 was found; instead, we found biallelic mutations in HSPA9, the gene that codes for mHSP70/mortalin, another highly conserved mitochondrial chaperone protein essential in mitochondrial protein import, folding, and degradation. The functional relationship between LONP1 and HSPA9 in mitochondrial protein chaperoning and the overlapping phenotypes of CODAS and EVEN-PLUS delineate a family of “mitochondrial chaperonopathies” and point to an unexplored role of mitochondrial chaperones in human embryonic morphogenesis.
Collapse
Affiliation(s)
- Beryl Royer-Bertrand
- Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland.,Centre for Molecular Diseases, Department of Pediatrics, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Silvia Castillo-Taucher
- Sección Genética, Hospital Clínico Universidad de Chile, and Sección Citogenética, Laboratorio, Clínica Alemana de Santiago, Santiago, Chile
| | - Rodrigo Moreno-Salinas
- Unidad de Genética, Hospital Regional Rancagua, Rancagua, Chile; and ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Tae-Joon Cho
- Division of Pediatric Orthopaedics, Seoul National University Children's Hospital, Seoul, Republic of Korea
| | - Jong-Hee Chae
- Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul, Republic of Korea
| | - Murim Choi
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Ok-Hwa Kim
- Department of Radiology, Woorisoa Children's Hospital, Saemalro, Guro-gu, Seoul 08291, Republic of Korea
| | - Esra Dikoglu
- Centre for Molecular Diseases, Department of Pediatrics, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Belinda Campos-Xavier
- Centre for Molecular Diseases, Department of Pediatrics, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Enrico Girardi
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Giulio Superti-Furga
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Luisa Bonafé
- Centre for Molecular Diseases, Department of Pediatrics, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Carlo Rivolta
- Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
| | - Sheila Unger
- Medical Genetics Service, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Andrea Superti-Furga
- Centre for Molecular Diseases, Department of Pediatrics, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,Department of Pediatrics and Pediatric Surgery, University of Lausanne and Lausanne University Hospital (CHUV), Lausanne, Switzerland
| |
Collapse
|
21
|
Dikoglu E, Alfaiz A, Gorna M, Bertola D, Chae JH, Cho TJ, Derbent M, Alanay Y, Guran T, Kim OH, Llerenar JC, Yamamoto G, Superti-Furga G, Reymond A, Xenarios I, Stevenson B, Campos-Xavier B, Bonafé L, Superti-Furga A, Unger S. Mutations in LONP1, a mitochondrial matrix protease, cause CODAS syndrome. Am J Med Genet A 2015; 167:1501-9. [PMID: 25808063 DOI: 10.1002/ajmg.a.37029] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 02/07/2015] [Indexed: 11/12/2022]
Abstract
Cerebral, ocular, dental, auricular, skeletal anomalies (CODAS) syndrome (MIM 600373) was first described and named by Shehib et al, in 1991 in a single patient. The anomalies referred to in the acronym are as follows: cerebral-developmental delay, ocular-cataracts, dental-aberrant cusp morphology and delayed eruption, auricular-malformations of the external ear, and skeletal-spondyloepiphyseal dysplasia. This distinctive constellation of anatomical findings should allow easy recognition but despite this only four apparently sporadic patients have been reported in the last 20 years indicating that the full phenotype is indeed very rare with perhaps milder or a typical presentations that are allelic but without sufficient phenotypic resemblance to permit clinical diagnosis. We performed exome sequencing in three patients (an isolated case and a brother and sister sib pair) with classical features of CODAS. Sanger sequencing was used to confirm results as well as for mutation discovery in a further four unrelated patients ascertained via their skeletal features. Compound heterozygous or homozygous mutations in LONP1 were found in all (8 separate mutations; 6 missense, 1 nonsense, 1 small in-frame deletion) thus establishing the genetic basis of CODAS and the pattern of inheritance (autosomal recessive). LONP1 encodes an enzyme of bacterial ancestry that participates in protein turnover within the mitochondrial matrix. The mutations cluster at the ATP-binding and proteolytic domains of the enzyme. Biallelic inheritance and clustering of mutations confirm dysfunction of LONP1 activity as the molecular basis of CODAS but the pathogenesis remains to be explored.
Collapse
Affiliation(s)
- Esra Dikoglu
- Centre des Maladies Moléculaires CHUV, University of Lausanne, Switzerland
| | - Ali Alfaiz
- Center for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Maria Gorna
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Deborah Bertola
- Genetics Unit, Instituto da Criança, HC/FMUSP, Sao Paulo, Brazil
| | - Jong Hee Chae
- Department of Orthopaedic Surgery, Seoul National Univ Children's Hospital, Seoul, South Korea
| | - Tae-Joon Cho
- Department of Orthopaedic Surgery, Seoul National Univ Children's Hospital, Seoul, South Korea
| | - Murat Derbent
- Pediatric Genetics Unit, Department of Pediatrics, Başkent University Faculty of Medicine, Ankara, Turkey
| | - Yasemin Alanay
- Pediatric Genetics, Department of Pediatrics, Acibadem University School of Medicine, Istanbul, Turkey
| | - Tulay Guran
- Division of Pediatric Endocrinology, Department of Pediatrics, Marmara University Hospital, Istanbul, Turkey
| | - Ok-Hwa Kim
- Radiology, Woorisoa Children's Hospital, Seoul, Korea
| | - Juan C Llerenar
- Centro de Genética Médica, Instituto Fernandes Fugueira/Fiocruz, Rio de Janeiro, Brazil
| | | | - Giulio Superti-Furga
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Alexandre Reymond
- Center for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland
| | | | | | | | - Luisa Bonafé
- Centre des Maladies Moléculaires CHUV, University of Lausanne, Switzerland
| | | | - Sheila Unger
- Medical Genetics Service, CHUV, University of Lausanne, Switzerland
| |
Collapse
|
22
|
Simsek-Kiper PO, Dikoglu E, Campos-Xavier B, Utine GE, Bonafe L, Unger S, Boduroglu K, Superti-Furga A. Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: A single case observation. Am J Med Genet A 2014; 164A:2667-71. [DOI: 10.1002/ajmg.a.36692] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 06/20/2014] [Indexed: 11/10/2022]
Affiliation(s)
- Pelin Ozlem Simsek-Kiper
- Unit of Pediatric Genetics Department of Pediatrics; Hacettepe University Medical Faculty; Ankara Turkey
- Division of Molecular Pediatrics Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Esra Dikoglu
- Division of Molecular Pediatrics Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Belinda Campos-Xavier
- Division of Molecular Pediatrics Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Gulen Eda Utine
- Unit of Pediatric Genetics Department of Pediatrics; Hacettepe University Medical Faculty; Ankara Turkey
| | - Luisa Bonafe
- Division of Molecular Pediatrics Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Sheila Unger
- Service of Medical Genetics University of Lausanne; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Koray Boduroglu
- Unit of Pediatric Genetics Department of Pediatrics; Hacettepe University Medical Faculty; Ankara Turkey
| | - Andrea Superti-Furga
- Division of Molecular Pediatrics Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| |
Collapse
|
23
|
Dikoglu E, Simsek-Kiper PO, Utine GE, Campos-Xavier B, Boduroglu K, Bonafé L, Superti-Furga A, Unger S. Homozygosity for a novel truncating mutation confirms TBX15
deficiency as the cause of Cousin syndrome. Am J Med Genet A 2013; 161A:3161-5. [DOI: 10.1002/ajmg.a.36173] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 07/18/2013] [Indexed: 11/06/2022]
Affiliation(s)
- Esra Dikoglu
- Division of Molecular Pediatrics; Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Pelin Ozlem Simsek-Kiper
- Pediatric Genetics Unit; Department of Pediatrics; Hacettepe University Faculty of Medicine; Ankara Turkey
| | - Gulen Eda Utine
- Pediatric Genetics Unit; Department of Pediatrics; Hacettepe University Faculty of Medicine; Ankara Turkey
| | - Belinda Campos-Xavier
- Division of Molecular Pediatrics; Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Koray Boduroglu
- Pediatric Genetics Unit; Department of Pediatrics; Hacettepe University Faculty of Medicine; Ankara Turkey
| | - Luisa Bonafé
- Division of Molecular Pediatrics; Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Andrea Superti-Furga
- Department of Pediatrics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - Sheila Unger
- Service of Medical Genetics; University of Lausanne, Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| |
Collapse
|
24
|
Durak Aras B, Aras I, Can C, Toprak C, Dikoglu E, Bademci G, Ozdemir M, Cilingir O, Artan S. Exploring the relationship between the severity of oligozoospermia and the frequencies of sperm chromosome aneuploidies. Andrologia 2012; 44:416-22. [DOI: 10.1111/j.1439-0272.2012.01298.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2012] [Indexed: 11/27/2022] Open
Affiliation(s)
- B. Durak Aras
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - I. Aras
- Department of Urology; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - C. Can
- Department of Urology; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - C. Toprak
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - E. Dikoglu
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - G. Bademci
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - M. Ozdemir
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - O. Cilingir
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| | - S. Artan
- Department of Medical Genetics; Medical Faculty; Eskişehir Osmangazi University; Eskisehir; Turkey
| |
Collapse
|